Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

SP2086 Pharmacokinetic Study in Renal Insufficiency Patients

23. juni 2016 oppdatert av: Jiangsu HengRui Medicine Co., Ltd.

A Parallel, Open Phase Ih Study to Access the Pharmacokinetic of SP2086 in Renal Insufficiency Patients

The purpose of the study is to investigate the SP2086 pharmacokinetic in Renal Insufficiency Patients.

Studieoversikt

Status

Fullført

Intervensjon / Behandling

Detaljert beskrivelse

This trial adopt in a parallel, open, single dose study design. The subject was divided into one of five groups according to the degree of renal Insufficiency, which including normal, mild, moderate, severe, and end-stage. All subjects were given SP2086 50mg, and collected the blood samples before and after the medicine taken.

Studietype

Intervensjonell

Registrering (Faktiske)

30

Fase

  • Fase 1

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 79 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • with a body mass index(BMI) between 19 and 28 Kg/m2;Weight:≥50Kg(male),≥45kg(female)
  • The endogenous creatinine clearance of subjects in groups must meet the standards of Ccr in renal function in installment:mild renal insufficiency:60-89 - ml/min;Moderate renal insufficiency: 30 to 59 ml/min;Severe renal insufficiency: 15-29 ml/min;End-stage renal disease: < 15 ml/min.Normal renal function: 90 ml/min or more.
  • Had signed the informed consent himself or herself voluntarily.

Exclusion Criteria:

  • Cannot tolerate oral medicine.
  • Not control or unstable cardiovascular, respiratory, liver, digestive, endocrine, hematopoietic, the mental or nerve system diseases.
  • Had the digestive surgery that could affect drug absorption.
  • The clinical significance of arrhythmia.
  • Acute hepatitis, chronic liver disease; ALT or AST value was 2 times greater than upper normal limit, Total bilirubin value was 1.5 times greater than upper normal limit.
  • HBV surface antigen, HCV antibody, or HIV antibody was positive.
  • history of drug allergy or allergic constitution or family history of allergy.
  • Had Used hormonal contraception within 3 months;
  • Had Used DPP - IV inhibitor within 2 weeks;
  • Had Used traditional Chinese medicine (Chinese herbs, Chinese patent medicine) within 2 weeks;
  • Had Used acid inhibitors within 2 weeks;
  • Alcohol, tobacco, drug abusers;alcohol abuse is defined as a day for regular alcohol consumption more than the following standards: beer 570 ml, light beer 750 ml, red wine 200 ml, white wine 60 ml, which including about 20g alcohol;Tobacco is defined as five or more per day.
  • 2 days before the randomization till to the end ,the patients can not ban alcohol, tobacco, or reference food or drink containing caffeine or xanthine , or vigorous exercise, or there are other factors that can affect drug absorption, distribution, metabolism and excretion
  • The patient had participated three times or more clinical trial in one year, or one time within 3 months.
  • Pregnancy or lactation women, or a fertility male or female is not willing to contraception during test.
  • History of blood donation or participate in blood donation, or by blood transfusion in 3 months prior to screening.
  • Researchers considered that there was any situation that may cause the participants can't finish this study or bring any obvious risk to subjects.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: health volunteers
this group patients were given SP2086 50mg only one time.
all subjects were given SP2086 50mg only one time.
Aktiv komparator: mild renal insufficiency
this group patients were given SP2086 50mg only one time.
all subjects were given SP2086 50mg only one time.
Aktiv komparator: moderate renal insufficiency
this group patients were given SP2086 50mg only one time.
all subjects were given SP2086 50mg only one time.
Aktiv komparator: severe renal insufficiency
this group patients were given SP2086 50mg only one time.
all subjects were given SP2086 50mg only one time.
Aktiv komparator: end-stage renal insufficiency
this group patients were given SP2086 50mg only one time.
all subjects were given SP2086 50mg only one time.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
The maximum plasma concentration (Cmax) of SP2086
Tidsramme: up to 96 hours
Cmax (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of SP2086
up to 96 hours
The maximum plasma concentration (Cmax) of SP2086 acid
Tidsramme: up to 96 hours
Cmax (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of a single dose of SP2086
up to 96 hours
The area under the plasma concentration-time curve (AUC) of SP2086
Tidsramme: up to 96 hours
AUC (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of SP2086
up to 96 hours
The area under the plasma concentration-time curve (AUC) of SP2086 acid
Tidsramme: up to 96 hours
AUC (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of a single dose of SP2086
up to 96 hours

Sekundære resultatmål

Resultatmål
Tidsramme
Antall frivillige med uønskede hendelser som et mål på sikkerhet og tolerabilitet
Tidsramme: opptil 96 timer
opptil 96 timer

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Jia Miao, P.H.D, West China Hospital

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. juni 2014

Primær fullføring (Faktiske)

1. januar 2015

Studiet fullført (Faktiske)

1. januar 2015

Datoer for studieregistrering

Først innsendt

3. januar 2016

Først innsendt som oppfylte QC-kriteriene

23. juni 2016

Først lagt ut (Anslag)

28. juni 2016

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

28. juni 2016

Siste oppdatering sendt inn som oppfylte QC-kriteriene

23. juni 2016

Sist bekreftet

1. juni 2016

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • HR-SP2086-Ih

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere